Compare Incyte Corporation (INCY) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Newmont Corporation — how do they compare? Incyte Corporation trades at $120.76 (market cap $24.54B), while Newmont Corporation trades at $118.07 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 5× Incyte Corporation's market cap, and Newmont Corporation pays a 0.89% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NEM | |
|---|---|---|
Market Cap | $24.54B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $131.95 |
52-Week Low | $81.61 | $67.38 |
Enterprise Value | $20.04B | $120.09B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Newmont (NEM) trades at $118.52, up 1.07% on the day, with strong earnings beats in recent quarters and a bullish analyst consensus. Technical indicators show mixed signals with RSI near overbought levels but moving averages supporting an uptrend. Recent news highlights resolution of a Nevada dispute with Barrick and solid Q2 2026 results, reinforcing operational stability.
Outlook remains positive with a $133 consensus price target, driven by robust cash flow and gold price strength. Risks include potential cost pressures and reliance on commodity cycles, but institutional buying and high buy ratings suggest confidence in near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
